Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

18 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Adasuve Articles

Alexza deal with Teva sets stage for Adasuve, say analysts

23 May 2013

Teva pays $40 million upfront to market Alexza's Adasuve in USA

9 May 2013

Positive EU regulatory news for Alexza and Ferrer, but not Gentium

22 February 2013

Positive recommendations from EMA's CHMP for Selincro, Adasuve and Perjeta

17 December 2012

FDA sets PDUFA date for Alexza's resubmission for Adasuve

8 July 2012

Alexza rockets on re-submission of Adasuve NDA

25 June 2012

FDA again rejects Alexza's Adasuve, citing manufacturing deficiencies

7 May 2012

PDUFA goal date for Alexza’s Adasuve extended, as Public Citizen says drug should not be approved

25 January 2012

ISTA Pharma rejects Valeant’s advances; Alexza could be for sale

19 December 2011

FDA advisory panel backs Alexza antipsychotic drug

15 December 2011

Showing 1-10 of 10 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Elan puts up formal "for sale" notice
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Elan puts up formal "for sale" notice
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS